Erythropoietin or Darbepoetin for patients with cancer - Meta-analysis based on individual patient data

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Bohlius, Julia ^a   Trelle, Sven ^b   Weingart, Olaf ^a   Schwarzer, Guido ^c   Brillant, Corinne ^a   Clarke, Mike J ^d   Djulbegovic, Benjamin ^e   Piper, Margret ^f   Rades, Dirk ^g   Seidenfeld, Jerome ^f   Somerfield, Mark ^h   Steensma, David ⁱ   Schumacher, Martin ^c   Engert, Andreas ^a   Egger, Matthias ^j  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c German Cochrane Center   (Germany)

^d UK COCHRANE CENTRE   (United Kingdom)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f Blue Cross and Blue Shield Association   (United States)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEMOGLOBIN; IRON; LACTATE DEHYDROGENASE; NAVELBINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PLATINUM DERIVATIVE; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE; VINCRISTINE;

ANEMIA; BODY MASS; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; ETHNIC DIFFERENCE; FOLLOW UP; HEAD AND NECK CANCER; HEMATOCRIT; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; HUMAN; HYPERTENSION; IRON THERAPY; LEUKOCYTE COUNT; META ANALYSIS; NEOPLASM; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 55049119973     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007303     Document Type: Review

References (89)

1. Akaike 1974 Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control 1974;19(6):716-23.
2. Amgen 2000 0161 2007 Amgen 2000 0161. Continuing reassment of the risks of erythropoiesis-stimulating agents (ESAs) administeres for the treatment of anemia associated with cancer chemotherapy. Hearings before the Sub Comm. on Oncologic Drugs Advisory Committee of the House Comm. on Department of Health and Human Services, Food and Drug Administration , Center for Drug Evaluation and Research 2007, May 10.
3. Amgen 2001 0103 2007 Amgen 2001 0103. Continuing reassment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with cancer chemotherapy. Hearings before the SubComm. on Oncologic Drugs Advisory Committee of the House Comm. on Department of Health and Human Services, Food and Drugs Administration, Center for Drug Evaluation and Research 2007, May 10.
4. Arcasoy 2003 Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 2003;307(4):999-1007.
5. Arcasoy 2005 Arcasoy MO, Amin K, Vollmer RT, Jiang X, Mark-Wahnefried W, Haroon ZA. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol 2005;18(3):421-30.
6. Barendsen 1982 Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982;8(11):1981-97.
7. Beyersmann 2007 Beyersmann J, Dettenkofer M, Bertz H, Schumacher M. A competing risks analysis of bloodstream infection after stem-cell transplantation using subdistribution hazards and cause-specific hazards. Stat Med 2007, July 17;26(30):5360-9.
8. Bohlius 2005 Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, et al.Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97(7):489-98.
9. Bohlius 2006 Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al.Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98(10):708-14.
10. Bottomley 2002 Bottomley A, Thomas R, van Steen K, Flechtner H, Djulbegovic B. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?. Lancet Oncology 2002;3:145-53.
11. Boucher 1998 Boucher KM, Slattery ML, Berry TD, Quesenberry C, Anderson K. Statistical methods in epidemiology: a comparison of statistical methods to analyze dose-response and trend analysis in epidemiologic studies. J Clin Epidemiol 1998;51(12):1223-33.
12. Brines 2000 Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al.Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; Vol. 97, issue 19:10526-31.
13. Brines 2004 Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, et al.Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101(41):14907-12.
14. Caro 2001 Caro JJ, Salas M, Ward A, Goss A. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantiative review. Cancer 2001;91(12):2214-21.
15. Cella 1997 Cella D. The functional assessment of cancer therapy-anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(Suppl 2):13-9.
16. Chang 2005 Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobain, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23(12):2597-605.
17. Clark 2002 Clark O, Adams JR, Bennett CL, Djulbegovic B. Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2002;2(1):23.
18. D'Andrea 1989 D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell 1989;57:277-85.
19. Dagnon 2005 Dagnon K, Pacary E, Commo F, Antoine M, Bernaudin M, Bernaudin JF, et al.Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res 2005;11(3):993-9.
20. DerSimonian 1986 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88.
21. Egger 2001 Egger M, Smith GD, O'Rourke K. Rationale, potentials, and promise of systematic reviews. Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. BMJ Publishing Group. 2001:3-19.
22. Eisenstein 2005 Eisenstein EL, Lemons PW, Tardiff BE, Schulman KA, Jolly MK, Califf RM. Reducing the costs of phase III cardiovascular clinical trials. Am Heart J 2005;149(3):482-8.
23. Elliot 2006 Elliot S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, et al.Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107(5):1892-5.
24. EPO GBR-07 2004 Luksenburg H, Weir A, Wager R. Epo GBR-07: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen Inc. and Procrit (epoetin alfa) Ortho Biotech L.P., for the treatment of anemia associated with cancer chemotherapy. Hearings before the SubComm. on Oncologic Drugs Advisory Committee of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research May 4, 2004.
25. EPO-CAN-15 2004 Luksenburg H, Weir A, Wager R. EPO-CAN-15: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen Inc and Procrit (epoetin alfa) Ortho Biotech L.P. for the treatment of anemia associated with cancer chemotherapy. Hearings before the SubComm. on Oncologic Drugs Advisory Committee of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research May 4, 2004.
26. Feldman 2006 Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 2006;66(2):135-45.
27. Francis 1998 Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Seminars in Thrombosis and Hemostasis 1998;24(2):93-109.
28. Glaspy 2005 Glaspy J, Berg R, Tomita D, Rossi G, Vadhan-Raj S. Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoietin alfa 40,000 U weekly (QW) in patients with chemotherapy-induced anemia (CIA). 41st ASCO annual meeting, Orlando. 2005; Vol. Abstract 8125.
29. Glaspy 2007 Glaspy J, Smith R, Aapro M, Ludwig H, Pinter T, Smakal M, et al.Results from a phase 3, randomised, double-blind, placebo-controlled study of Darbepoetin Alfa for the treatment of anemia in cancer patients not receiving chemotherapy or radiotherapy. 12th Congress of the European Hematology Association, Vienna, Austria. June 7-10, 2007.
30. GOG-191 2004 Luksenburg H, Weir A, Wager R. GOG-191: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen Inc. and Procrit (epoetin alfa) Ortho Biotech L.P., for the treatment of Anemia associated with cancer chemotherapy. Hearings before the SubComm. on Oncologic Drugs Advisory Committee of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research 2004.
31. Goodnough 2003 Goodnough LT. Risks of blood transfusion. Crit Care Med 2003;31(12 suppl):678-86.
32. Goodnough 2005 Goodnough LT. Risks of blood transfusion. Anesthesiol Clin North America 2005;23(2):241-52.
33. Groopman 1999 Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91(19): 1616-34.
34. Halstenson 1991 Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, et al.Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clinical Pharmacology and Therapeutics 1991;50(6):702-12.
35. Hardee 2007 Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y, Rabbani ZN, et al.Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS ONE 2007;2(6):e549.
36. Hedenus 2003 Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, et al.Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122(3):394-403.
37. Henke 2003 Henke M, Laszig R, Ruebe C, Schaefer U, Haase KD, Schilcher B, et al.Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
38. Henke 2006 Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, et al.Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 2006;24(29):4708-13.
39. Higgins 2002 Higgins JP, Thompson SG. Quantifying heterogeneity in meta-analysis. Stat Med 2002;21(11):1539-58.
40. Higgins 2006 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. Chichester: John Wiley & Sons, Ltd 2006 (updated September 2006).
41. Hockel 1993 Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, et al.Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy Oncology 1993;26:45-50.
42. Holzner 2002 Holzner B, Kemmler G, Greil R, Kopp M, Zeimet A, Raderer M, et al.The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 2002;13(6):965-73.
43. Joiner 1997 Joiner MC, Van der Kogel AJ. The linear-quadratic approach to fractionation and calculation of isoeffect relationships. Steel GG, editor. Basic Clinical Radiobiology. Oxford University Press. 1997:106-12.
44. Koury 1988 Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988;71:524-7.
45. Koury 1990 Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990;248(4953):378-81.
46. Koury 1991 Koury ST, Bondurant MC, Koury MJ, Semenza GL. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 1991;77(11):2497-503.
47. Lai 1986 Lai PH, Everett R, Wang FF, Arakawa T, Goldwasser E. Structural characterization of human erythropoietin. Journal of Biological Chemistry 1986 March;5(261 (7)):3116-21.
48. Langensiepen 2002 Langensiepen S, Bohlius J, Seidenfeld J, Piper M, Bennett CL, Schwarzer G, et al.Erythropoietin for patients with malignant disease. (Protocol for a Cochrane Review). Oxford Update Software 2002.
49. Leo 2006 Leo C, Horn LC, Rauscher C, Hentschel B, Liebmann A, Hildebrandt G, et al.Expression of erythropoietin and erythropoietin receptor in cervical cancer and relationship to survival, hypoxia, and apoptosis. Clin Cancer Res 2006;12(23):6894-900.
50. Levine 2003 Levine MN, Lee AY, Kakkar AK. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. Journal of Thrombosis and Haemostasis 2003;1(7):1456-63.
51. Leyland-Jones 2003 Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncology 2003;4:459-60.
52. Leyland-Jones 2005 Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al.Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23(25):5960-72.
53. Lind 2002 Lind M, Vernon C, Cruickshank D, Wilkinson P, Littlewood T, Stuart N, et al.The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 2002;86(8):1243-9.
54. Littlewood 2003 Littlewood TJ, Zagari M, Pallister C, Perkins A. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 2003;8(1):99-107.
55. Ludwig 2001 Ludwig H, Strasser K. Symptomatology of anemia. Seminars in Oncology. 2001; 28(2, Suppl.8):7-14.
56. Ludwig 2004 Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al.The European Cancer Anaemia Survey (ECAS): a large multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40(15):2293-306.
57. Luksenburg 2004 Luksenburg H, Weir A, Wager R. ODAC 2004: Safety concerns associated with Aranesp (darbepoetin alfa) Amgen Inc and Procrit (epoetin alfa) Ortho Biotech L.P. for the treatment of anemia associated with cancer chemotherapy. Hearings before the SubComm on Oncologic Drugs Advisory Committee of the House Comm. on Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research May 4, 2004.
58. Machtay 2004 Machtay M, Pajak T, Suntharalingam M, Hershock D, Stripp DC, Cmelak A, et al.Definitive radiotherapy +/- erythropoietin for squamous cell cacinoma of the head and neck: preliminary report of RTOG 99-03. International Journal of Radiation Oncology, Biology and Physics. 2004; Vol. 60, issue Suppl. 1:132.
59. McBroom 2005 McBroom JW, Acs G, Rose GS, Krivak TC, Mohyeldin A, Verma A. Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol 2005;99(3):571-7.
60. Mcentegart 1999 Mcentegart DJ, Jadhav SP, Brown T, Channon EJ. Checks of case record forms versus the database for efficacy variables when validation programs exist. Drug Information Journal 33 1999:101-7.
61. Moebus 2007 Moebus V, Lueck H, Thomssen C, Harbeck N, Nitz U, Kreienberg R, et al.The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial). J Clin Oncol. 2007; Vol. 25, Abstract: 18S.
62. Mohyeldin 2005 Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G, et al.Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005;7(5):537-43.
63. Osterborg 2007 Osterborg A, Aapro M, Cornes P, Haselbeck A, Hayward CR, Jelkmann W. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 2007;43(3):510-9.
64. Overgaard 2006 Overgaard J. Interim Analysis of DAHANCA 10. 2006, Dec 1.
65. Ribatti 2007a Ribatti D, Marzullo A, Longo V, Poliani L. Schwann cells in neuroblastoma express erythropoietin. J Neurooncol 2007;82(3):327-8.
66. Ribatti 2007b Ribatti D, Poliani PL, Longo V, Mangieri D, Nico B, Vacca A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology 2007;50(5): 636-41.
67. Rosenzweig 2004 Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. Journal of Pain& Symptom Management 2004;27(2):185-90.
68. Royston 1999 Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999;28(5):964-74.
69. Schrijvers 1999 Schrijvers D, Highley M, De Bruyn E, Van Oosterom AT, Vermorken JB. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 1999 February; 10(2):147-53;10(2):147-53.
70. Sehata 2007 Sehata N, Walker I, Meyer R, Haynes AE, Imrie K, and Cancer Care Ontario's Program in Evidence-Based Care's Systematic Disease Site Group. Treatment for anemia with erythropoietic agents in patients with non-myeloid hematological malignancies: a clinical practice guideline. Report 2007:6-12.
71. Seidenfeld 2001 Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, et al.Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta analysis of controlled clinical trials. J Natl Cancer Inst 2001;93(16):1204-14.
72. Simmonds 2005 Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review ofmethods used in practice. Clin Trials 2005;2(3):209-17.
73. Smith 2005 Smith CT, Williamson PR, Marson AG. Investigating heterogeneity in an individual patient datameta-analysis of time to event outcomes. Stat Med 2005;24(9):1307-19.
74. Smith 2007 Smith TC, Willamson PR. A comparison ofmethods for fixed effects meta-analysis of individual patient data with time to event outcomes. Clinical Trials 2007;4:621-30.
75. Spivak 2005 Spivak JL. The anaemia of cancer: death by a thousand cuts. Nature Reviews Cancer 2005;5(7):543-55.
76. Sterne 2001 Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001;54(10):1046-55.
77. Stewart 1995 Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. Stat Med 1995;14(19):2057-79.
78. Storring 1998 Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematology 1998;100:79-89.
79. Toy 2005 Toy P, Popovsky MA, Abraham E, Ambruso DR, Holness LG, Kopko PM, et al.Transfusion-related acute lung injury: definition and review. Crit Care Med 2005 April;33(4):721-6.
80. Um 2007 Um M, Gross AW, Lodish HF. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 2007;19(3):634-45.
81. van Walraven 2004 van Walraven C, Davis D, Forster AJ, Wells GA. Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol 2004;57(7):672-82.
82. Vaupel 2001 Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001;18(4): 243-59.
83. Vaupel 2002 Vaupel P, Thews O, Mayer A, Hockel S, Hockel M. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level?. Strahlenther Onkol 2002;178(12):727-31.
84. Vaupel 2005 Vaupel P, Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus Clin Biol 2005;12(1):5-10.
85. Vogelzang 1997 Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, et al.Patient, caregiver, and oncologist perceptions of cancer-related fatique: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34(3 Suppl 2):4-12.
86. Wood 1995 Wood PA, Hrushesky JM. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. Journal of Clinical Investigation 1995;95:1650-9.
87. Wright 2007 Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, et al.Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25(9):1027-32.
88. Yasuda 2003 Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, et al.Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021-9.
89. Zajda 2007 Zajda K, Krzakowski M. Epoetin delta in the management of anemia in cancer patients. J Clin Oncol. 2007; Vol. 25:18S Abstract.